Medical diagnostic standards for Group A streptococcal infections utilize a variety of rapid antigen tests, including cassettes and dipsticks from manufacturers like Abbott and Becton Dickinson. These tools provide qualitative results to identify infections, while separate clinical protocols manage soft tissue infections such as cellulitis through physical examination and targeted antibiotics.
The identification of Group A streptococcal infections relies on a specialized array of rapid diagnostic tests designed to detect the presence of the bacteria. These tests, which vary by manufacturer and format, are categorized by their detection limits and whether they are delivered as a cassette or a test strip.
Rapid Test Specifications and Detection Limits
Different diagnostic tools offer varying levels of sensitivity, measured in colony-forming units (CFU) or organisms per test. Several manufacturers provide qualitative results through different delivery methods.
Abbott: Offers the Clearview exact Strep A cassette and dipstick, both with a detection limit of 5×104 organisms/test. The Alere TestPack Plus Strep A cassette is also available, though its specific detection limit is not listed; however, it is noted as Yes (if symptoms persist)
regarding its qualitative status.
Becton Dickinson: The BD Veritor plus system group A Strep cassette identifies levels between 1×105 to 5×104 CFU/ml.
Biopanda Reagents: Provides both a cassette and a test strip version of the Strep A rapid test, each with a limit of 1E+05 organisms/swab.
Quidel: The Sofia Strep A FIA cassette shows a detection range of 1.86×104 to 9.24×103 CFU/test and a time frame of 5 to 6.
Other options include the Bionexia Strep A plus cassette from Biomerieux, which detects 1×104 organisms/swab, and the Biosynex Strep A cassette, which identifies 1×105 bacteria/swab.
Comparative Performance of Diagnostic Brands
The OSOM Strep A test from Sekisui diagnostics is listed as a qualitative “Yes” despite its specific detection limit being unknown.
| Manufacturer/Test | Format | Detection Limit | Qualitative “Yes” Status |
|---|---|---|---|
| NADAL Strep A / Plus / Scan | Cassette/Strip | 1.5×105 organisms/swab | No |
| QuikRead Go (Orion Diagnostica) | N/A | 7×104 CFU/swab | Not known |
| Bionexia Strep A dipstick | Test strip | Not known | Not known |
The data shows a clear divide in manufacturer success; specifically, all NADAL variations—including the Strep A, Strep A plus, and Strep A scan test from nal von minden GmbH—are marked as No regarding their qualitative status. The QuikRead Go Strep A test kit from Orion Diagnostica lists a detection limit of 7×104 CFU/swab and a time of “Less than 7.”
Clinical Management of Soft Tissue Infections
While rapid tests target specific bacterial infections like Strep A, broader soft tissue infections require a different diagnostic approach. Cellulitis and soft tissue infections encompass a diverse range of diseases, spanning from uncomplicated cellulitis to necrotizing fasciitis.
Unlike the lab-based antigen tests used for sore throats, cellulitis is primarily a clinical diagnosis. This means medical providers make the determination based on a patient’s history and a physical examination. Imaging is utilized selectively, primarily to characterize associated osteomyelitis or purulent soft tissue infections.
Treatment Foundations and Prevention
The approach to treating these infections is twofold: surgical and pharmacological. The foundations of treatment are the drainage of purulence and the administration of antibiotics.
Antibiotic therapy is not generic; it is targeted at the most likely cause of the specific infection. To prevent these conditions from recurring, the primary strategy is the management of predisposing conditions.
The contrast between the two diagnostic paths is stark. For a sore throat, the process is a quantitative search for organisms using specific cassettes or strips. For soft tissue infections, the process is an observational clinical diagnosis where the physical state of the tissue dictates the intervention. Patients should consult qualified healthcare professionals for clinical diagnosis and treatment plans.
Worth a look
